NEW YORK, NY / ACCESSWIRE / June 12, 2017 / Lexicon's shares took off on Friday after the company released positive late-stage type-1 diabetes trial results regarding its novel investigational agent Sotagliflozin. Adamis Pharmaceuticals also saw some gains despite any news, but we're inching closer to June 15th which could be when the FDA decides on the candidate, based on the review timeline of 6 months for resubmissions.
RDI Initiates Coverage on:
Lexicon Pharmaceuticals, Inc.
Adamis Pharmaceuticals Corporation
Lexicon Pharmaceuticals, Inc.'s shares had a lift off on Friday and closed in the green up 6.77%. The big move came after the company released top-line results from its late-stage type-1 diabetes trial. The Phase 3 inTandem3 study of Lexicon's sotagliflozin showed that it met its primary endpoint. Sotagliflozin is the company's orally-delivered small molecule compound that is currently in development for the treatment of type 1 and type 2 diabetes mellitus. It is an investigational dual SGLT1 and SGLT2 inhibitor. In the 24-week treatment period, results indicated that the compound had a "generally well tolerated safety profile." Lead investigator of the trial, Satish Garg M.D., commented, "The results achieved with sotagliflozin in the inTandem3 study are scientifically and clinically important and significant. If approved, sotagliflozin may potentially be the first option as an adjunct to insulin to improve glycemic control for patients with type 1 diabetes."
Access RDI's Lexicon Pharmaceuticals Research Report at:
Adamis Pharmaceuticals Corporation's shares closed up 4.88% on Friday on volume that was considerably larger than usual. There was no remarkable news to explain the move. The company, which develops products in the therapeutic areas of respiratory disease and allergy, has seen its shares rise over 36% YTD. One of the company's most advanced candidates is an Epinephrine Pre-filled Syringe used in emergency treatment for anaphylaxis. Anaphylaxis is an acute allergic reaction to an antigen to which the body has become hypersensitive. It can be fatal. Adamis' Pharma's Epinephrine Pre-filled Syringe was developed under 505(b)(2) regulatory pathway and is designed to be a more cost-effective alternative than Mylan's EpiPen. Investors are waiting for June 15th, as the FDA may decide by then on the candidate. It was previously turned down in 2016 and 2015. Could this time finally be a win?
Access RDI’s Adamis Pharmaceuticals Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.